Akero to Present New Efruxifermin Data at Liver Meeting 2025
Akero Therapeutics will deliver two oral presentations and a poster at AASLD’s The Liver Meeting 2025, highlighting 96-week Phase...
Strategies for High-Cost Claims & Pharma Partnerships
AscellaHealth will place two senior leaders on the Self-Insurance Institute of America’s national conference stage in Phoenix on October...
MannKind’s scPharma Buy Accelerates Cardiometabolic Growth
MannKind has closed its acquisition of scPharmaceuticals, bringing Furoscix, a subcutaneous furosemide injection for fluid overload in chronic heart...
Neurogastrx NG101 Aims to Reduce GLP-1 Nausea, Vomiting
Neurogastrx will present proof-of-concept, placebo-controlled data for NG101 (metopimazine mesylate) in semaglutide-induced nausea and vomiting at ObesityWeek 2025 on...
New Atea Data Sparks Hope for Best-in-Class HCV Treatment
Atea Pharmaceuticals will present new data at AASLD’s Liver Meeting 2025 in Washington, DC, backing its fixed-dose combination of...
Relmada Adds Expert Oncologist to Promising Advisory Board
Relmada Therapeutics has appointed Max Kates, MD, a leading urologic oncologist from Johns Hopkins and chair of the large,...
Akero Presents New Efruxifermin Phase 2b Data at AASLD
Akero Therapeutics will present new 96-week Phase 2b data for efruxifermin at the AASLD Liver Meeting 2025, including two...
Ocular Therapeutix™ to Attend Upcoming Science Conferences
Ocular Therapeutix will use the October ophthalmology meeting circuit to advance its retina ambitions, spotlighting new data for its...
OXB’s Surging US Growth With New North Carolina Facility
OXB has acquired an FDA-approved, commercial-scale viral vector manufacturing facility in Durham, North Carolina, from a subsidiary of National...
Lexeo Announces Positive LX2006 Data for FA Cardiomyopathy
Lexeo Therapeutics reported that the FDA is open to a pooled-data strategy supporting an accelerated approval filing for LX2006,...